These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Kawasaki disease in East Mazandaran, Islamic Republic of Iran, 1997-2002. Saffar MJ; Reshidighader F East Mediterr Health J; 2005; 11(1-2):28-35. PubMed ID: 16532668 [TBL] [Abstract][Full Text] [Related]
24. A girl with extremely refractory Kawasaki disease: an instructive case with unusual course and outcome. Kossiva L; Karanassios E; Papadopoulos G; Karavanaki K Cardiol Young; 2012 Aug; 22(4):461-5. PubMed ID: 21933460 [TBL] [Abstract][Full Text] [Related]
25. Kawasaki disease with pulmonary nodules and coronary artery involvement: a report of two cases and a review of the literature. Akagi K; Abe J; Tanaka K; Tomotaki S; Iki Y; Ueda K; Nakata M; Yoshioka T; Shiota M; Hata A; Watanabe K; Hata D Int J Rheum Dis; 2017 Nov; 20(11):1862-1864. PubMed ID: 26200440 [No Abstract] [Full Text] [Related]
26. Preventing Long-Term Cardiac Damage in Pediatric Patients With Kawasaki Disease. Williams K J Pediatr Health Care; 2017; 31(2):196-202. PubMed ID: 27592169 [TBL] [Abstract][Full Text] [Related]
27. What do we know about Kawasaki disease? Kucińska B; Wróblewska-Kałuzewska M Med Sci Monit; 2000; 6(6):1227-31. PubMed ID: 11208484 [TBL] [Abstract][Full Text] [Related]
28. [Kawasaki disease: what you need to know]. Bajolle F; Laux D Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712 [TBL] [Abstract][Full Text] [Related]
29. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease]. Kobayashi T; Inoue Y; Morikawa A Nihon Rinsho; 2008 Feb; 66(2):332-7. PubMed ID: 18260333 [TBL] [Abstract][Full Text] [Related]
30. Incomplete Kawaski disease: are we missing it? Billoo AG; Lone SW; Siddiqui S; Atiq H J Pak Med Assoc; 2009 Jan; 59(1):42-3. PubMed ID: 19213377 [TBL] [Abstract][Full Text] [Related]
33. Kawasaki disease. Epidemiology, late prognosis, and therapy. Barron KS Rheum Dis Clin North Am; 1991 Nov; 17(4):907-19. PubMed ID: 1767080 [TBL] [Abstract][Full Text] [Related]
34. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Lau AC; Duong TT; Ito S; Yeung RS Arthritis Rheum; 2009 Jul; 60(7):2131-41. PubMed ID: 19565485 [TBL] [Abstract][Full Text] [Related]
35. [Intravenous immunoglobulin-resistant Kawasaki disease with hemophagocytosis]. Servel AC; Vincenti M; Darras JP; Lalande M; Rodière M; Filleron A Arch Pediatr; 2012 Jul; 19(7):741-4. PubMed ID: 22652521 [TBL] [Abstract][Full Text] [Related]
36. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study]. DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF; Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869 [TBL] [Abstract][Full Text] [Related]
37. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370 [TBL] [Abstract][Full Text] [Related]